Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Eculizumab and drug-induced haemolytic-uraemic syndrome

5 Sept 2013

Abstract excerpt

The monoclonal anti-C5 antibody eculizumab has been successfully tested in atypical haemolytic-uraemic syndrome (aHUS), with or without mutations in the regulatory proteins of the alternative pathway of the complement, and less convincingly in enterohaemorrhagic Escherichia coli-associated HUS. Here, we report a patient with mitomycin-C-induced HUS unresponsive to plasma exchanges. Eculizumab infusion was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood groups and transfusion
Share to Complement system in diseases
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26120441
DOI: 10.1093/ckj/sft078

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eculizumab and drug-induced haemolytic-uraemic syndromePMID 26120441Read ↗

Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumabSemantic proximity Read ↗

New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.Semantic proximity Read ↗

Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysisSemantic proximity Read ↗

aHUS caused by complement dysregulation: new therapies on the horizon.Semantic proximity Read ↗

Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B.Semantic proximity Read ↗

Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.Semantic proximity Read ↗

Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings.Semantic proximity Read ↗

A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome.Semantic proximity Read ↗

Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic SyndromeSemantic proximity Read ↗

Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation.Semantic proximity Read ↗

Atypical HUS: time to take stock of current guidelines and outcome measures?Semantic proximity Read ↗

Eculizumab for atypical haemolytic uraemic syndrome: what next?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.